Clinical Trials Logo

Filter by:
NCT ID: NCT00375596 Withdrawn - Clinical trials for Allergic Conjunctivitis

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a new allergy medication

NCT ID: NCT00377494 Withdrawn - Clinical trials for Plasmodium Falciparum Malaria

CS DNA MVA Trial in Mampong, Ghana

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of 2 doses of a malaria vaccine (DNA) followed by a dose of another type of malaria vaccine (MVA) given as a "booster." Forty-eight adults in Ghana, ages 18-50 years, will participate for 17 months. They will be randomly assigned to 1 of 4 treatment groups. Group 1 will receive the DNA malaria vaccine at months 0 and 1, and the booster at month 7. Group 2 will receive a rabies vaccine at months 0 and 1, and an injection containing no vaccine at month 7. Group 3 will receive the DNA malaria vaccine at months 5 and 6, and the booster at month 7. Group 4 will receive the rabies vaccine at months 5 and 6, and an injection containing no vaccine at month 7. Blood samples and information regarding health problems that may occur after vaccination will be collected.

NCT ID: NCT00378235 Withdrawn - Clinical trials for Recurrent Malignant Glioma

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13-receptor positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells.

NCT ID: NCT00378781 Withdrawn - Cancer Clinical Trials

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Start date: n/a
Phase: N/A
Study type: Interventional

RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection. It is not yet known whether heparin is more effective than M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection. PURPOSE: This randomized clinical trial is studying heparin to see how well it works compared with M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection.

NCT ID: NCT00380458 Withdrawn - Clinical trials for Sleep Apnea, Obstructive

Study to Evaluate Recovery From Postoperative Pain After Sleep Apnea Surgery

Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess whether tonsillectomy and UPPP performed using the study device to treat Obstructive Sleep Apnea (OSA) symptoms in adults is associated with less postoperative pain during the 21-day postoperative recovery period compared to electrocautery dissection.

NCT ID: NCT00380835 Withdrawn - Clinical trials for Metastatic Breast Cancer

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the incidence of cardiac toxicity of amrubicin when administered to patients with metastatic breast cancer.

NCT ID: NCT00382330 Withdrawn - Vulvar Cancer Clinical Trials

Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if regular and daily repeated application of the ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.

NCT ID: NCT00385554 Withdrawn - HIV Infections Clinical Trials

Botswana Study of UC-781 Vaginal Microbicide

Start date: n/a
Phase: Phase 1
Study type: Interventional

This study will test the safety, side effects, and acceptability of two strengths of UC-781 gel when used by women and men in Botswana for two weeks.

NCT ID: NCT00389753 Withdrawn - Hydration of Scars Clinical Trials

Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure

Start date: n/a
Phase: N/A
Study type: Interventional

Comparison between use of Aruba Aloë formula F-BC-096 and control.

NCT ID: NCT00396968 Withdrawn - Clinical trials for Myelodysplastic Syndromes

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

AMD3100 given in combination with busulfan, fludarabine (and thymoglobulin (ATG) for unrelated or HLA nonidentical donors) preparative regimen in patients with acute myelogenous leukemia (AML) / myelodysplastic syndromes (MDS). This study aims to determine if in AML and MDS patients there is a reduction of malignant cells and enhanced elimination of the leukemia as assessed by progression free survival. Secondary goals will be to assess effects on engraftment, graft versus host disease (GVHD) and immune reconstitution.